Erratum to: NGF eye-drops topical administration in patients with retinitis pigmentosa, a pilot study

Falsini, Benedetto; Iarossi, Giancarlo; Chiaretti, Antonio; Ruggiero, Antonio; Manni, Luigi; Galli‐Resta, Lucia; Corbo, Giovanni; Abed, Edoardo

doi:10.1186/s12967-016-0800-5

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, in a rat model of optic nerve crush, rhNGF eye drops reduced the co-expression of NOGO-A and p75NTR at glial scar-forming cells at crush site borders, and improved TrkA/p75NTR and proNGF/NGF ratios, thus resulting in activation of survival and regeneration program during the first 2 weeks after injury [66]. Importantly, rhNGF eye drops were well tolerated in clinical trials [78,79] and therefore can be a potential treatment of optic neuropathies. Nevertheless, although rhNGF counteracted the enhancement of p75NTR, NOGO-R, and ROCK2 in the retina 7 days after injury, it had a modest effect on axon regrowth by 14 days after crush.…”

Section: Protection Of Retina Vs Optic Nerve: Lessons From Neuroprotmentioning

confidence: 98%

Optic Nerve Regeneration: Considerations on Treatment of Acute Optic Neuropathy and End-Stage Disease

Mesentier-Louro

Liao

2019

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Purpose of Review Acute and chronic optic neuropathies lead to irreversible vision loss, prompting considerations of regenerative therapy. Th e insult commonly occurs primarily in the anterior optic nerve, which leads to degeneration of retinal ganglion cells (RGCs) and their axons and loss of oligodendrocytes. We review important aspects of optic nerve regeneration and animal models of disease. Recent Findings Preclinical studies in animals showed that approaches that improve RGC survival and axon regeneration include neurotrophic factor delivery, genetic manipulation, visual stimulation, and cell therapies, but impact on glia must be also considered. While intravitreal delivery of molecules has been most commonly used, direct targeting of the optic nerve should be considered. Summary Treatment can differ if targeting acute or subacute vs. chronic optic neuropathies, depending on whether most RGC axons and somata are still present and salvageable, or if somata and axons are gone and need to be replaced. Combined neuron-and glia-directed treatments may lead to more successful vision restoration.

show abstract

Section: Protection Of Retina Vs Optic Nerve: Lessons From Neuroprotmentioning

confidence: 98%

Optic Nerve Regeneration: Considerations on Treatment of Acute Optic Neuropathy and End-Stage Disease

Mesentier-Louro

Liao

2019

Curr Ophthalmol Rep

View full text Add to dashboard Cite

show abstract

Nerve Growth Factor Role on Retinal Ganglion Cell Survival and Axon Regrowth: Effects of Ocular Administration in Experimental Model of Optic Nerve Injury

et al. 2018

View full text Add to dashboard Cite

Retinal ganglion cell (RGC) degeneration occurs within 2 weeks following optic nerve crush (ONC) as a consequence of reduced retro-transport of growth factors including nerve growth factor (NGF). The hypothesis that intravitreal (ivt) and eye drop (ed) administration of recombinant human NGF (rhNGF) might counteract ONC in adult rats is explored in this study. We found that both ivt- and ed-rhNGF reduced RGC loss and stimulated axonal regrowth. Chiefly, survival and regenerative effects of rhNGF were associated with a reduction of cells co-expressing Nogo-A/p75NTR at crush site borders, which contribute to glia scar formation following nerve injury, and induce further degeneration. We also found that ocular application of rhNGF reduced p75NTR and proNGF and enhanced phosphorylation of TrkA and its intracellular signals at retina level. Nogo-R and Rock2 expression was also normalized by ed-rhNGF treatment in both ONC and contralateral retina. Our findings that ocular applied NGF reaches and exerts biological actions on posterior segment of the eye give a further insight into the neurotrophin diffusion/transport through eye structures and/or their trafficking in optic nerve. In addition, the use of a highly purified NGF form in injury condition in which proNGF/p75NTR binding is favored indicates that increased availability of mature NGF restores the balance between TrkA and p75NGF, thus resulting in RGC survival and axonal growth. In conclusion, ocular applied NGF is confirmed as a good experimental paradigm to study mechanisms of neurodegeneration and regeneration, disclose biomarkers, and time windows for efficacy treatment following cell or nerve injury.

show abstract

Management of Children with Optic Gliomas and Neurofibromatosis Type 1

Attinà

Maurizi

Triarico

et al. 2020

Biomed. Pharmacol. J.

View full text Add to dashboard Cite

Optic pathway gliomas (OPG) are a common cancer in children with neurofibromatosis type 1. OPGs can cause clinical symptoms such as reduction of visual acuity, alterations of the visual field, pallor of the optical papilla, strabismus, endocrinological alterations up to diencephalic syndrome.The current guidelines provide for wait and see as the main approach if the tumor is not causing visual deterioration and adopting treatment only in the event of significant impairment of the visual function. Therefore, it is essential to early detect the visual deterioration changes as well as the identification of children eligible for treatment.

show abstract

Erratum to: NGF eye-drops topical administration in patients with retinitis pigmentosa, a pilot study

Cited by 4 publications

References 1 publication

Optic Nerve Regeneration: Considerations on Treatment of Acute Optic Neuropathy and End-Stage Disease

Optic Nerve Regeneration: Considerations on Treatment of Acute Optic Neuropathy and End-Stage Disease

Nerve Growth Factor Role on Retinal Ganglion Cell Survival and Axon Regrowth: Effects of Ocular Administration in Experimental Model of Optic Nerve Injury

Management of Children with Optic Gliomas and Neurofibromatosis Type 1

Contact Info

Product

Resources

About